BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31634797)

  • 1. Unlocking the concealed targets using system biology mapping for Alzheimer's disease.
    Joshi P; Kawade V; Dhulap S; Goel M
    Pharmacol Rep; 2019 Dec; 71(6):1104-1107. PubMed ID: 31634797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease.
    Morsy A; Trippier PC
    J Alzheimers Dis; 2019; 72(s1):S145-S176. PubMed ID: 31594236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease.
    Rao CV; Asch AS; Carr DJJ; Yamada HY
    Aging Cell; 2020 Mar; 19(3):e13109. PubMed ID: 31981470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery.
    Zhou Y; Fang J; Bekris LM; Kim YH; Pieper AA; Leverenz JB; Cummings J; Cheng F
    Alzheimers Res Ther; 2021 Jan; 13(1):24. PubMed ID: 33441136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.
    Vargas DM; De Bastiani MA; Zimmer ER; Klamt F
    Alzheimers Res Ther; 2018 Jun; 10(1):59. PubMed ID: 29935546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
    Behl T; Kaur I; Fratila O; Brata R; Bungau S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
    Chatterjee P; Roy D; Rathi N
    J Alzheimers Dis; 2018; 61(1):53-65. PubMed ID: 29199645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Articulating target-mining techniques to disinter Alzheimer's specific targets for drug repurposing.
    G N S HS; Marise VLP; Rajalekshmi SG; Burri RR; Krishna Murthy TP
    Comput Methods Programs Biomed; 2022 Jul; 222():106931. PubMed ID: 35724476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Applications of Bioinformatics in Target Identification and Drug Discovery for Alzheimer's Disease.
    Singh SK; Kumar A; Singh RB; Ghosh P; Bajad NG
    Curr Top Med Chem; 2022; 22(26):2153-2175. PubMed ID: 36305125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():376-401. PubMed ID: 30273552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical genetics-based drug repurposing for Alzheimer's disease.
    Zhang XZ; Quan Y; Tang GY
    Brain Res Bull; 2015 Jan; 110():26-9. PubMed ID: 25446738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.
    Kuo YC; Rajesh R
    Expert Rev Neurother; 2019 Jul; 19(7):623-652. PubMed ID: 31109210
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
    Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
    EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the development of new drugs in Alzheimer's disease.
    Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B
    J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
    Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
    PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood.
    Bourdakou MM; Fernández-Ginés R; Cuadrado A; Spyrou GM
    Redox Biol; 2023 Nov; 67():102881. PubMed ID: 37696195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease.
    Li H; Wang X; Yu H; Zhu J; Jin H; Wang A; Yang Z
    Curr Neuropharmacol; 2018; 16(6):758-768. PubMed ID: 29086699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.